Veru Inc., founded in Wisconsin in 1971. The company is a late-stage clinical biopharmaceutical company focused on the development of new drugs for the treatment of cardiometabolic and inflammatory diseases. The company's drug development program includes two late-stage new chemical entities, enobosarm and sabizabulin. 

Veru

Veru Price Target Up 11.11% to $25.50

Veru shares surge 16.59% premarket after positive Phase 2b trial results and FDA regulatory clarity for enobosarm in obesity treatment.

Veru: Canaccord Genuity initiates Buy rating with $25 PT.

VERU News